千金药业: 株洲千金药业股份有限公司关于上海证券交易所并购重组审核委员会审核公司发行股份及支付现金购买资产暨关联交易事项会议安排的公告

Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., plans to acquire 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payment, pending approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2]. Group 1 - The company’s board of directors guarantees that the announcement contains no false records, misleading statements, or major omissions, and they bear individual and joint responsibility for the authenticity, accuracy, and completeness of the content [1]. - The Shanghai Stock Exchange's M&A Review Committee is scheduled to hold its 12th review meeting on August 18, 2025, to review the company's application for this transaction [1]. - The transaction is subject to approval by the Shanghai Stock Exchange and registration with the China Securities Regulatory Commission, with uncertainties regarding the approval process and timeline [2].